TIGIT and plasma cell myeloma: Moreover, TIGIT-deficient mice show increased survival when challenged with VK*MYC myeloma cell lines [35]; however, a recent study revealed that TIGIT-deficient mice did not reject the implanted B16F10 and MC38 more efficiently compared with wild-type (WT) mice [36].